Denali Therapeutics Inc.

MUN:4DN Stock Report

Market Cap: €1.8b

Denali Therapeutics Management

Management criteria checks 3/4

Denali Therapeutics' CEO is Ryan Watts, appointed in Aug 2015, has a tenure of 9.75 years. total yearly compensation is $6.56M, comprised of 10.5% salary and 89.5% bonuses, including company stock and options. directly owns 1.69% of the company’s shares, worth €30.25M. The average tenure of the management team and the board of directors is 6.3 years and 7.2 years respectively.

Key information

Ryan Watts

Chief executive officer

US$6.6m

Total compensation

CEO salary percentage10.52%
CEO tenure9.8yrs
CEO ownership1.7%
Management average tenure6.3yrs
Board average tenure7.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ryan Watts's remuneration changed compared to Denali Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$454m

Dec 31 2024US$7mUS$690k

-US$423m

Sep 30 2024n/an/a

-US$427m

Jun 30 2024n/an/a

-US$420m

Mar 31 2024n/an/a

-US$137m

Dec 31 2023US$8mUS$670k

-US$145m

Sep 30 2023n/an/a

-US$124m

Jun 30 2023n/an/a

-US$128m

Mar 31 2023n/an/a

-US$371m

Dec 31 2022US$9mUS$645k

-US$326m

Sep 30 2022n/an/a

-US$303m

Jun 30 2022n/an/a

-US$284m

Mar 31 2022n/an/a

-US$286m

Dec 31 2021US$13mUS$610k

-US$291m

Sep 30 2021n/an/a

US$30m

Jun 30 2021n/an/a

US$56m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$9mUS$589k

US$71m

Sep 30 2020n/an/a

-US$228m

Jun 30 2020n/an/a

-US$216m

Mar 31 2020n/an/a

-US$215m

Dec 31 2019US$5mUS$567k

-US$198m

Sep 30 2019n/an/a

-US$66m

Jun 30 2019n/an/a

-US$55m

Mar 31 2019n/an/a

-US$52m

Dec 31 2018US$6mUS$545k

-US$36m

Compensation vs Market: Ryan's total compensation ($USD6.56M) is above average for companies of similar size in the German market ($USD1.79M).

Compensation vs Earnings: Ryan's compensation has been consistent with company performance over the past year.

CEO

Ryan Watts (48 yo)

9.8yrs

Tenure

US$6,557,662

Compensation

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

Leadership Team

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder9.8yrsUS$6.56m1.69%
€ 30.3m
Alexander Schuth
Co-Founder10.2yrsUS$4.02m0.53%
€ 9.5m
Marc Tessier-Lavigne
Co-Founder & Independent Directorno dataUS$371.97k1.46%
€ 26.1m
Carole Ho
Chief Medical Officer & Head of Development9.9yrsUS$4.02m0.26%
€ 4.7m
Tyler Nielsen
Senior Vice President of Corporate Financeno datano datano data
Dana Andersen
Chief Technical and Manufacturing Officer6.8yrsno datano data
Joe Lewcock
Chief Scientific Officer4.8yrsno datano data
Laura Hansen
Vice President of Investor Relations5.3yrsno datano data
Chris Walsh
General Counsel6.3yrsno datano data
Mark Rowen
Vice President of Corporate Development2.3yrsno datano data
Cindy Dunkle
Chief People Officerno datano datano data
Katie Peng
Chief Commercial Officer3.7yrsno datano data

6.3yrs

Average Tenure

51yo

Average Age

Experienced Management: 4DN's management team is seasoned and experienced (6.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Ryan Watts
Co-Founder10.2yrsUS$6.56m1.69%
€ 30.3m
Marc Tessier-Lavigne
Co-Founder & Independent Director10.2yrsUS$371.97k1.46%
€ 26.1m
Vicki Sato
Independent Chairperson10.1yrsUS$399.47k0.074%
€ 1.3m
Jay Flatley
Independent Director10.1yrsUS$384.47k0.24%
€ 4.3m
Eric Reiman
Member of Scientific Advisory Boardno datano datano data
David Schenkein
Independent Director10.1yrsUS$379.47k0.046%
€ 821.5k
David Holtzman
Member of Scientific Advisory Board4.5yrsno datano data
Peter Klein
Independent Director7.2yrsUS$389.43k0.015%
€ 264.9k
Jennifer Cook
Independent Director6.5yrsUS$369.47k0.014%
€ 246.8k
Steve Krognes
Independent Director3yrsUS$359.47k0.56%
€ 9.9m
Stacie Weninger
Member of Scientific Advisory Board4.3yrsno datano data
Henrik Zetterberg
Member of Scientific Advisory Board6.1yrsno datano data

7.2yrs

Average Tenure

63yo

Average Age

Experienced Board: 4DN's board of directors are considered experienced (7.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 22:13
End of Day Share Price 2025/04/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Denali Therapeutics Inc. is covered by 25 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Caroline PalomequeBerenberg
Tazeen AhmadBofA Global Research